Latest & greatest articles for liraglutide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on liraglutide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on liraglutide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for liraglutide

41. [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)]

[Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V. [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 316. 2015 Final publication URL Indexing Status Subject

Health Technology Assessment (HTA) Database.2016

42. [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V]

[Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment (...) according to §35a Social Code Book V] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V. [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und

Health Technology Assessment (HTA) Database.2016

43. [Insulin degludec/liraglutide (Addendum to Commission A15-15)]

[Insulin degludec/liraglutide (Addendum to Commission A15-15)] Insulin degludec/liraglutid (addendum zum Auftrag A15-15) [Insulin degludec/liraglutide (Addendum to Commission A15-15)] Insulin degludec/liraglutid (addendum zum Auftrag A15-15) [Insulin degludec/liraglutide (Addendum to Commission A15-15)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation IQWiG. Insulin degludec/liraglutid (addendum zum Auftrag A15-15). [Insulin degludec/liraglutide (Addendum to Commission A15-15)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 327. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Hypoglycemic Agents; Insulin, Long-Acting Language Published German Country of organisation Germany English summary There is no English language summary available

Health Technology Assessment (HTA) Database.2016

44. Liraglutide (Saxenda) and obesity: there are still no satisfactory weight loss drugs

Liraglutide (Saxenda) and obesity: there are still no satisfactory weight loss drugs Prescrire IN ENGLISH - Spotlight ''Liraglutide (Saxenda°) and obesity: there are still no satisfactory weight loss drugs'', 1 January 2016 {1} {1} {1} | | > > > Liraglutide (Saxenda°) and obesity: there are still no satisfactory weight loss drugs Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...)  |   |  Spotlight Liraglutide (Saxenda°) and obesity: there are still no satisfactory weight loss drugs FEATURED REVIEW On average, daily liraglutide injections for one year help patients lose only a few kilograms compared with placebo, and weight is gradually regained after treatment discontinuation. Patients who are overweight or obese should not be exposed to the frequent gastrointestinal disorders and the risk of pancreatitis associated with long-term, high-dose liraglutide

Prescrire2016

45. Liraglutide: Weighing the evidence for weight loss?

Liraglutide: Weighing the evidence for weight loss? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,400 family physicians, family medicine residents and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca August 15, 2016 (...) Liraglutide: Weighing the evidence for weight loss? Clinical Question: Does liraglutide reduce weight and improve health in obese patients? Bottom-line: Once daily Liraglutide 3.0 mg injections reduce weight 3.4%-4.6 % over one year and one in 3-4 patients treated will get a 5% weight loss over placebo. Adverse events (like nausea and vomiting) will cause one in 17 to stop liraglutide. The effect was not sustained beyond drug cessation and long-term health effects in obese non-diabetics are unknown

Tools for Practice2016

46. Insulin degludec/liraglutide (Xultophy®)

Insulin degludec/liraglutide (Xultophy®) Insulin degludec/liraglutide (Xultophy®) Insulin degludec/liraglutide (Xultophy®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Insulin degludec/liraglutide (Xultophy®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC (...) ), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2544. 2015 Authors' conclusions Insulin degludec/liraglutide (Xultophy®) is recommended as an option for restricted use within NHS Wales. Insulin degludec/liraglutide (Xultophy®) is licensed for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a glucagon-like peptide

Health Technology Assessment (HTA) Database.2015

47. Insulin degludec/liraglutide (Xultophy) - for the treatment of adults with type 2 diabetes mellitus

Insulin degludec/liraglutide (Xultophy) - for the treatment of adults with type 2 diabetes mellitus Final Appraisal Recommendation Advice No: 2715 – October 2015 Insulin degludec/liraglutide (Xultophy ® ? ) 100 units/3.6 mg per ml solution for injection Submission by Novo Nordisk Ltd Additional note(s): • Insulin degludec/liraglutide (Xultophy ® ? ) should be prescribed by brand name to avoid medication errors. In reaching the above recommendation AWMSG has taken account of the appraisal (...) . Recommendation of AWMSG Insulin degludec/liraglutide (Xultophy ® ? ) is recommended as an option for restricted use within NHS Wales. Insulin degludec/liraglutide (Xultophy ® ? ) is licensed for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a glucagon-like peptide protein-1 (GLP-1) receptor agonist or basal insulin do not provide adequate glycaemic control. Insulin degludec

All Wales Medicines Strategy Group2015

48. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial 26179619 2015 10 21 2016 07 28 2017 02 20 1463-1326 17 11 2015 Nov Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. 1056-64 (...) 10.1111/dom.12539 To confirm the superiority, compared with placebo, of adding liraglutide to pre-existing basal insulin analogue ± metformin in adults with inadequately controlled type 2 diabetes [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)]. In this 26-week, double-blind, parallel-group study, conducted in clinics or hospitals, 451 subjects were randomized 1 : 1 to once-daily liraglutide 1.8 mg (dose escalated from 0.6 and 1.2 mg/day, respectively, for 1 week each; n = 226) or placebo (n

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

49. Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)

Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Insulin degludec/Liraglutid – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A15-15 (...) Insulin degludec/liraglutide – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-15 Version 1.0 Insulin degludec/liraglutide – Benefit assessment acc. to §35a SGB V 30 July 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Insulin degludec/liraglutide – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint

Institute for Quality and Efficiency in Healthcare (IQWiG)2015

50. Liraglutide in Weight Management.

Liraglutide in Weight Management. Liraglutide in Weight Management. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26510028 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 29;373(18):1781-2. doi: 10.1056/NEJMc1509759. Liraglutide in Weight Management. ; . Comment on [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] PMID: 26510028 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental

NEJM2015

51. Liraglutide in Weight Management.

Liraglutide in Weight Management. Liraglutide in Weight Management. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26510029 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 29;373(18):1779. doi: 10.1056/NEJMc1509759#SA1. Liraglutide in Weight Management. , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26510029 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here: > > PubMed

NEJM2015 Full Text: Link to full Text with Trip Pro

52. Liraglutide in Weight Management.

Liraglutide in Weight Management. Liraglutide in Weight Management. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26510030 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 29;373(18):1779-80. doi: 10.1056/NEJMc1509759#SA2. Liraglutide in Weight Management. . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26510030 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here

NEJM2015 Full Text: Link to full Text with Trip Pro

53. Liraglutide in Weight Management.

Liraglutide in Weight Management. Liraglutide in Weight Management. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26510031 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 29;373(18):1780. doi: 10.1056/NEJMc1509759#SA3. Liraglutide in Weight Management. , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26510031 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here: > > PubMed

NEJM2015 Full Text: Link to full Text with Trip Pro

54. Liraglutide in Weight Management.

Liraglutide in Weight Management. Liraglutide in Weight Management. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26510032 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 29;373(18):1780-1. doi: 10.1056/NEJMc1509759#SA4. Liraglutide in Weight Management. . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26510032 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here: > > PubMed

NEJM2015 Full Text: Link to full Text with Trip Pro

55. Liraglutide in Weight Management.

Liraglutide in Weight Management. Liraglutide in Weight Management. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26510033 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 29;373(18):1781. doi: 10.1056/NEJMc1509759#SA5. Liraglutide in Weight Management. . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26510033 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here: > > PubMed

NEJM2015 Full Text: Link to full Text with Trip Pro

57. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study

Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study 26179187 2015 09 25 2016 06 30 2017 02 20 1463-1326 17 10 2015 Oct Diabetes, obesity & metabolism Diabetes Obes Metab Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients (...) with type 2 diabetes: a 26-week randomized phase III study. 974-83 10.1111/dom.12534 To examine the efficacy and safety of once-weekly dulaglutide monotherapy (0.75 mg) compared with placebo and once-daily liraglutide (0.9 mg) in Japanese patients with type 2 diabetes. This was a phase III, 52-week (26-week primary endpoint), randomized, double-blind, placebo-controlled, open-label comparator (liraglutide) trial comparing 492 Japanese patients with type 2 diabetes (dulaglutide, n = 281; liraglutide, n = 141

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

58. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. 26284720 2015 08 19 2015 09 03 2016 10 17 1538-3598 314 7 2015 Aug 18 JAMA JAMA Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. 687-99 10.1001/jama.2015.9676 Weight loss of 5% to 10% can improve type 2 diabetes and related comorbidities. Few safe, effective weight-management drugs are currently (...) available. To investigate efficacy and safety of liraglutide vs placebo for weight management in adults with overweight or obesity and type 2 diabetes. Fifty-six-week randomized (2:1:1), double-blind, placebo-controlled, parallel-group trial with 12-week observational off-drug follow-up period. The study was conducted at 126 sites in 9 countries between June 2011 and January 2013. Of 1361 participants assessed for eligibility, 846 were randomized. Inclusion criteria were body mass index of 27.0

JAMA2015 Full Text: Link to full Text with Trip Pro

59. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. IMPORTANCE: Weight loss of 5% to 10% can improve type 2 diabetes and related comorbidities. Few safe, effective weight-management drugs are currently available. OBJECTIVE: To investigate efficacy and safety of liraglutide vs placebo for weight management in adults with overweight or obesity and type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Fifty-six-week randomized (2 (...) % to 10.0%. INTERVENTIONS: Once-daily, subcutaneous liraglutide (3.0 mg) (n = 423), liraglutide (1.8 mg) (n = 211), or placebo (n = 212), all as adjunct to 500 kcal/d dietary deficit and increased physical activity (≥150 min/wk). MAIN OUTCOMES AND MEASURES: Three coprimary end points: relative change in weight, proportion of participants losing 5% or more, or more than 10%, of baseline weight at week 56. RESULTS: Baseline weight was 105.7 kg with liraglutide (3.0-mg dose), 105.8 kg with liraglutide (1.8

JAMA2015

60. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. 26132939 2015 07 03 2015 07 07 2016 10 25 1533-4406 373 1 2015 Jul 02 The New England journal of medicine N. Engl. J. Med. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. 11-22 10.1056/NEJMoa1411892 Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue (...) subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight. At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had

NEJM2015 Full Text: Link to full Text with Trip Pro